New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences

2 nd Annual Essentials in Primary Care
Fall Conference
Friday, November 11, 2011
Rivaroxaban - Xarelto
• Patients with any degree of renal impairment with
concurrent use of P-gp and weak to moderate
CYP3A4 inhibitors may have significant increases in
exposure which may increase bleeding risk
• Avoid concomitant use of rivaroxaban with drugs
that are combined P-gp and strong CYP3A4 inducers
(e.g., carbamazepine, phenytoin, rifampin, St. John’s
wort). Consider increasing the rivaroxaban dose if
these drugs must be co-administered
Rivaroxaban - Xarelto
• Avoid the use of rivaroxaban in patients with severe
renal impairment (CrCl